Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 6, 2007, Pages 877-884

  Tu, Chuan Tao ^c   Guo, Jin Sheng ^c   Wang, Manner ^c   Wang, Ji Yao ^a,b  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NONE

Author keywords

Cyclooxygenase 2; Liver fibrosis; Portal hypertension; Rofecoxib

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2 INHIBITOR; EOSIN; HEMATOXYLIN; LAMININ; ROFECOXIB; THROMBOXANE B2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETERIZATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME IMMUNOASSAY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; LIVER INJURY; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; STAINING; STELLATE CELL; WESTERN BLOTTING;

EID: 34250327199     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04867.x     Document Type: Article

References (33)

1. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal hypertension. J. Hepatol. 2000 32 : 141 56.
2. Rockey DC. Vascular mediators in the injured liver. Hepatology 2003 37 : 4 12.
3. Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000 118 : 1261 5.
4. Foegh ML, Ramwell PW. The eicosanoids: prostaglandins, thromboxanes, leuotrienes & related compounds. In : Katzung BG, ed. Basic and Clinical Pharmacology. San Francisco : The McGraw-Hill Companies, 2001 311 25.
5. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996 271 : 33157 60.
6. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem. Pharmacol. 2003 65 : 153 9.
7. Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 2000 59 : 1207 16.
8. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 2004 31 : 2 11.
9. Mohammed NA, Abd El-Aleem SA, El-Hafiz HA, McMahon RF. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J. Clin. Pathol. 2004 57 : 350 4.
10. Yamamoto H, Kondo M, Nakamori S et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver cirrhosis. Gastroenterology 2003 125 : 556 71.
11. Yokoyama Y, Xu H, Kresge N et al. Role of thromboxane A2 in early BDL-induced portal hypertension. Am. J. Physiol. 2003 284 : G453 60.
12. Graupera M, García-Pagán JC, Abraldes JG et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003 37 : 172 81.
13. Birney Y, Redmond EM, Sitzmann JV, Cahill PA. Eicosanoids in cirrhosis and portal hypertension. Prostaglandins Other Lipid Mediat. 2003 72 : 3 18.
14. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 2002 21 : 473 82.
15. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol. Res. 2003 26 : 1 9.
16. Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab. Invest. 2002 82 : 767 74.
17. Ihn H. Pathogenesis of fibrosis: role of TGF-β and CTGF. Curr. Opin. Rheumatol. 2002 14 : 681 5.
18. Suzuma K, Naruse K, Suzuma I et al. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J. Biol. Chem. 2000 275 : 40 25 31.
19. Rosmorduc O, Wendum D, Corpechot C et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am. J. Pathol. 1999 155 : 1065 73.
20. Corpechot C, Barbu V, Wendum D et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002 35 : 1010 21.
21. Yoshiji H, Kuriyama S, Yoshii J et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003 52 : 1347 54.
22. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004 126 : 886 94.
23. Iñiguez MA, Rodríguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol. Med. 2003 9 : 73 8.
24. Miura S, Tatsuguchi A, Wada K et al. Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts. Am. J. Physiol. 2004 287 : G444 51.
25. Nakamura T, Akiyoshi H, Saito I, Sato K. Adenovirus-mediated gene expression in the septal cells of cirrhotic rat livers. J. Hepatol. 1999 30 : 101 5.
26. Guo JS, Cho CH, Liu ESL, Choy HT, Wang JY, Koo MWL. Antiangiogenic effect of a highly selective coclooxygenase-2 inhibitor on gastric ulcer healing in rats. Toxicol. Appl. Pharmacol. 2002 183 : 41 5.
27. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 1991 13 : 372 4.
28. Nakayama Y, Takahara T, Miyabayashi C et al. Ultrastructural localization of type IV collagen and laminin in Disse space of rat liver with carbon tetrachloride induced fibrosis. Liver 1991 11 : 260 71.
29. Neubauer K, Krüger M, Quondamatteo F, Knittel T, Saile B, Ramadori G. Transforming growth factor-β1 stimulates the synthesis of basement membrane proteins laminin, collagen type IV and entactin in rat liver sinusoidal endothelial cells. J. Hepatol. 1999 31 : 692 702.
30. Wack KE, Ross MA, Zegarra V, Sysko LR, Watins SC, Stolz DB. Sinusoidal ultrastructure evaluated during the revascularization of regenerating rat liver. Hepatology 2001 33 : 363 78.
31. Uchio K, Graham M, Dean NM, Rosenbaum J, Desmoulière A. Down-regulation of connective tissue growth factor and type-1 collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen. 2004 12 : 60 6.
32. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Prac. Gastroenterol. Hepatol. 2004 1 : 98 105.
33. Kawada N, Klein H, Decker K. Eicosanoid-mediated contractility of hepatic stellate cells. Biochem. J. 1992 285 : 367 71.